JPMorgan analyst Richard Vosser upgraded Roche (RHHBY) to Neutral from Underweight with a price target of CHF 350, up from CHF 230. The firm adjusted ratings in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
- Roche price target raised to CHF 290 from CHF 255 at Morgan Stanley